Trials / Withdrawn
WithdrawnNCT01878136
Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Rush University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the hypothesis that the administration of intraventricular tPA reduces the rates of cerebral vasospasm and ventriculoperitoneal shunt-dependent hydrocephalus in patients with aneurysmal subarachnoid hemorrhage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tissue Plasminogen Activator | Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain) |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2013-06-14
- Last updated
- 2015-11-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01878136. Inclusion in this directory is not an endorsement.